Company · CIK 0001875558 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Nuvectis Pharma, Inc. · NVCT
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 AForm 4 → | Aug 5, 5:26 pm EDT | Michael J. CarsonVice President, Finance | 30,000 | — | — | 230,118 | — | |
| Jun 30, 2026 PForm 4 → | Jul 1, 1:41 pm EDT | Marlio Charles Mosseri10% Owner | 50,000 | $18.32 | $916,000 | 3,186,576 | +1.59% | |
| Jun 30, 2026 PForm 4 → | Jul 1, 1:39 pm EDT | Ron BentsurChairman & CEO, Director, 10% Owner | 12,500 | $20.00 | $250,000 | 3,688,424 | +0.34% | |
| Jun 11, 2026 AForm 4 → | Jun 12, 4:12 pm EDT | Kenneth HobermanDirector | 35,000 | — | — | 168,140 | — | |
| Jun 11, 2026 AForm 4 → | Jun 12, 4:11 pm EDT | James F Oliviero IIIDirector | 35,000 | — | — | 122,828 | — | |
| Jun 11, 2026 AForm 4 → | Jun 12, 4:11 pm EDT | Juan SanchezDirector | 35,000 | — | — | 113,380 | — | |
| Jun 11, 2026 AForm 4 → | Jun 12, 4:10 pm EDT | Matthew L. KaplanDirector | 35,000 | — | — | 159,760 | — |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.